JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Home・Lista de Ações・Cogent Biosciences Inc

Cogent Biosciences Inc

Fechado

36.16 -1.07

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

36.15

Máximo

37.21

Indicadores-chave
By Trading Economics
Rendimento	-22M -102M
Funcionários	258
EBITDA	-30M -109M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+41.53% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	645M 6.3B
Abertura anterior	37.23
Fecho anterior	36.16

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

4.88 / 5.87 Suporte e Resistência

Cogent Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de abr. de 2026, 23:33 UTC

Ações em Alta

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 de abr. de 2026, 23:24 UTC

Ganhos

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 de abr. de 2026, 23:15 UTC

Notícias Principais

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 de abr. de 2026, 22:46 UTC

Ganhos

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 de abr. de 2026, 22:37 UTC

Ganhos

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 de abr. de 2026, 22:15 UTC

Ganhos

Notícias Principais

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 de abr. de 2026, 23:33 UTC

Conversa de Mercado

Notícias Principais

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 de abr. de 2026, 23:31 UTC

Ganhos

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 de abr. de 2026, 23:31 UTC

Ganhos

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 de abr. de 2026, 23:30 UTC

Ganhos

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 de abr. de 2026, 23:30 UTC

Ganhos

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 de abr. de 2026, 23:19 UTC

Conversa de Mercado

Ganhos

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 de abr. de 2026, 23:09 UTC

Ganhos

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 de abr. de 2026, 23:03 UTC

Conversa de Mercado

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 de abr. de 2026, 23:01 UTC

Notícias Principais

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 de abr. de 2026, 22:51 UTC

Ganhos

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 de abr. de 2026, 22:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 de abr. de 2026, 22:48 UTC

Conversa de Mercado

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 de abr. de 2026, 22:40 UTC

Conversa de Mercado

Notícias Principais

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 de abr. de 2026, 22:32 UTC

Ganhos

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 de abr. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 de abr. de 2026, 22:22 UTC

Ganhos

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 de abr. de 2026, 22:17 UTC

Conversa de Mercado

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 de abr. de 2026, 22:14 UTC

Ganhos

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 de abr. de 2026, 22:14 UTC

Ganhos

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 de abr. de 2026, 22:07 UTC

Conversa de Mercado

Notícias Principais

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Comparação entre Pares

Variação de preço

Cogent Biosciences Inc Previsão

Preço-alvo

By TipRanks

41.53% parte superior

Previsão para 12 meses

Média 51.8 USD 41.53%

Máximo 64 USD

Mínimo 35 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

4.88 / 5.87Suporte e Resistência

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.